Literature DB >> 25787048

The need for a disease-specific prospective pregnancy registry for multiple sclerosis (MS).

Sura Alwan1, Christina D Chambers2, Vincent T Armenti3, A Dessa Sadovnick4.   

Abstract

Multiple sclerosis (MS) is the most commonly acquired neurological disorder affecting young adults of reproductive age with an approximately 3:1 female to male ratio. Although pregnancy is not contraindicated in MS, data are limited regarding pregnancy outcome among MS patients, and the safety or risk to the fetus associated with most maternal MS treatments, such as disease modifying therapies (DMTs), during pregnancy is unknown. We review available epidemiological and registry data on MS and pregnancy and discuss the need to initiate a North American Multiple Sclerosis Pregnancy Registry that will prospectively identify pregnancies in women with MS, obtain information on the disease, and its treatment during gestation and lactation and follow the children to determine their health status.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Birth outcome; Multiple sclerosis; Pregnancy; Pregnancy registry; Reproduction

Mesh:

Substances:

Year:  2014        PMID: 25787048     DOI: 10.1016/j.msard.2014.10.001

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  7 in total

Review 1.  An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis.

Authors:  Caila Vaughn; Aisha Bushra; Channa Kolb; Bianca Weinstock-Guttman
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

Review 2.  The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.

Authors:  Gabriel Pardo; David E Jones
Journal:  J Neurol       Date:  2017-09-06       Impact factor: 4.849

3.  Pregnancy rates and outcomes in women with and without MS in the United States.

Authors:  Maria K Houtchens; Natalie C Edwards; Gary Schneider; Kevin Stern; Amy L Phillips
Journal:  Neurology       Date:  2018-09-28       Impact factor: 9.910

4.  Pregnancy Outcomes in Men and Women Treated With Teriflunomide. A Population-Based Nationwide Danish Register Study.

Authors:  Johanna Balslev Andersen; Julie Yoon Moberg; Tim Spelman; Melinda Magyari
Journal:  Front Immunol       Date:  2018-11-23       Impact factor: 7.561

5.  Impairment and restrictions in possibly benign multiple sclerosis.

Authors:  Laura Melanie Schaefer; Jana Poettgen; Anja Fischer; Stefan Gold; Jan-Patrick Stellmann; Christoph Heesen
Journal:  Brain Behav       Date:  2019-03-18       Impact factor: 2.708

6.  The road to conception for women with multiple sclerosis.

Authors:  Dessa Sadovnick; Maria Criscuoli; Irene Yee; Robert Carruthers; Alice Schabas; Penelope Smyth
Journal:  Mult Scler J Exp Transl Clin       Date:  2021-07-15

Review 7.  Patient experience and practice trends in multiple sclerosis - clinical utility of fingolimod.

Authors:  Jong-Mi Lee; May H Han
Journal:  Patient Prefer Adherence       Date:  2015-05-21       Impact factor: 2.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.